Roche: positive results from study on Hemlibra
(CercleFinance.com) - Roche has announced that after the Haven 3 study, its Hemlibra (emicizumab) reduced bleeds treated by 96% compared with no prophylaxis in type A hemophilia without factor VIII inhibitors.
In this randomised, polycentric phase III study, 152 patients (adults and children of at least 12 years old), received Hemlibra prophylaxis weekly or fortnightly.
The company added that according to the results of the Haven 4 study, Hemlibra taken every four weeks provided "statistically significant control" of bleeding in patients with or without factor VIII inhibitors.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
In this randomised, polycentric phase III study, 152 patients (adults and children of at least 12 years old), received Hemlibra prophylaxis weekly or fortnightly.
The company added that according to the results of the Haven 4 study, Hemlibra taken every four weeks provided "statistically significant control" of bleeding in patients with or without factor VIII inhibitors.
Copyright (c) 2018 CercleFinance.com. All rights reserved.